Techbio firm Evaxion posts Q3 net income of $4.6 mln

Evaxion A/S

06/11/2025 12:44

Overview

Evaxion Q3 net income $4.6 mln, a turnaround from $1.9 mln loss last year

Revenue of $7.5 mln in Q3, primarily from MSD option exercise

Evaxion extends cash runway to second half of 2027 after MSD payment

Outlook

Company highlights ongoing partnership discussions amid financial market uncertainties

Evaxion extends cash runway to second half of 2027

Company aims to enter at least one more partnership deal in coming months

Result Drivers

Research and development (R&D) expenses were $3.1 million for the period ending September 30, 2025, compared to $2.6 million last year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
$4.62 mln
Q3 Basic EPS
$0.01
Q3 Pretax Profit
$4.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Evaxion A/S is $11.00, about 48.5% above its November 5 closing price of $5.66

Press Release: ID:nGNX94BchG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)